Repertoire Immune Medicines inks $189m Series B

Repertoire Immune Medicines, a clinical-stage biotech company, has secured $189 million in Series B financing.

Repertoire Immune Medicines, a clinical-stage biotech company, has secured $189 million in Series B financing. The investors included Flagship Pioneering, Softbank Vision Fund 2i, the Public Sector Pension Investment Board, the Alaska Permanent Fund and Invus.

Source: Press Release